atazanavir alvogen 150 mg
remedica ltd - cipru - atazanavirum - caps. - 150mg - antivirale cu actiune directa inhibitori de proteaza
atazanavir alvogen 200 mg
remedica ltd - cipru - atazanavirum - caps. - 200mg - antivirale cu actiune directa inhibitori de proteaza
atazanavir alvogen 300 mg
remedica ltd - cipru - atazanavirum - caps. - 300mg - antivirale cu actiune directa inhibitori de proteaza
ritonavir accord 100 mg
accord healthcare limited - marea britanie - ritonavirum - compr. film. - 100mg - antivirale cu actiune directa inhibitori de proteaza
ritonavir accord 100 mg
pharmadox healthcare ltd. - malta - ritonavirum - compr. film. - 100mg - antivirale cu actiune directa inhibitori de proteaza
fromilid uno 500 mg comprimate cu eliberare prelungită
krka d.d., novo mesto - clarithromycinum - comprimate cu eliberare prelungită - 500 mg
rigevidon drajeuri 0,03 mg + 0,15 mg
gedeon richter plc - ethinylestradiolum + levonorgestrelum - drajeuri - 0,03 mg + 0,15 mg
artizia drajeuri 0,02 mg + 0,075 mg
zentiva k.s. - drajeuri - 0,02 mg + 0,075 mg
lynparza
astrazeneca ab - olaparib - neoplasme ovariene - agenți antineoplazici - ovarian cancerlynparza este indicat ca monoterapie pentru:tratament de întreținere pentru pacienții adulți cu avansate (figo stadiile iii și iv) brca1/2-mutant (germline și/sau somatice) de înaltă calitate epitelial ovarian, al trompelor uterine sau cancer peritoneal primar care sunt în răspuns (completă sau parțială) după finalizarea prima linie de chimioterapie pe bază de platină. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 și 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. pacienții ar trebui să au fost tratați anterior cu o antraciclină și un taxan în (neo)adjuvantă sau metastatic dacă pacienții nu au fost potrivite pentru aceste tratamente (a se vedea secțiunea 5. pacientele cu receptori hormonali (hr)-pozitiv cancer de san ar trebui, de asemenea, au progresat pe sau după o prealabilă terapie endocrine, sau să fie considerate nepotrivite pentru terapia endocrină. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.
azalia 75 micrograme
gedeon richter plc. - ungaria - desogestrelum - compr. film. - 75micrograme - contraceptive hormonale pentru uz sistemic progestative